Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


Identification of potential therapeutic targets in prostate cancer through a cross-species approach.

Jurmeister S, Ramos-Montoya A, Sandi C, Pértega-Gomes N, Wadhwa K, Lamb AD, Dunning MJ, Attig J, Carroll JS, Fryer LG, Felisbino SL, Neal DE.

EMBO Mol Med. 2018 Mar;10(3). pii: e8274. doi: 10.15252/emmm.201708274.


MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer.

Pettersson A, Gerke T, Penney KL, Lis RT, Stack EC, Pértega-Gomes N, Zadra G, Tyekucheva S, Giovannucci EL, Mucci LA, Loda M.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):201-207. doi: 10.1158/1055-9965.EPI-17-0637. Epub 2017 Nov 15.


Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer.

Pinto F, Pértega-Gomes N, Vizcaíno JR, Andrade RP, Cárcano FM, Reis RM.

Oncotarget. 2016 May 17;7(20):28891-902. doi: 10.18632/oncotarget.8499.


Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.

Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Esmaeili M, Selth LA, Zecchini HI, Luko K, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, Vowler SL, Zecchini VR, Shaw G, Hessenkemper W, Russell R, Mohammed H, Stefanos N, Lynch AG, Grigorenko E, D'Santos C, Taylor C, Lamb A, Sriranjan R, Yang J, Stark R, Dehm SM, Rennie PS, Carroll JS, Griffiths JR, Tavaré S, Mills IG, McEwan IJ, Baniahmad A, Tilley WD, Neal DE.

J Natl Cancer Inst. 2015 Dec 11;108(5). doi: 10.1093/jnci/djv371. Print 2016 May.


Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer.

Pertega-Gomes N, Vizcaino JR, Felisbino S, Warren AY, Shaw G, Kay J, Whitaker H, Lynch AG, Fryer L, Neal DE, Massie CE.

Oncotarget. 2015 Aug 28;6(25):21675-84.


A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.

Pertega-Gomes N, Felisbino S, Massie CE, Vizcaino JR, Coelho R, Sandi C, Simoes-Sousa S, Jurmeister S, Ramos-Montoya A, Asim M, Tran M, Oliveira E, Lobo da Cunha A, Maximo V, Baltazar F, Neal DE, Fryer LG.

J Pathol. 2015 Aug;236(4):517-30. doi: 10.1002/path.4547.


Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer.

Valença I, Pértega-Gomes N, Vizcaino JR, Henrique RM, Lopes C, Baltazar F, Ribeiro D.

J Cell Mol Med. 2015 Apr;19(4):723-33. doi: 10.1111/jcmm.12481. Epub 2015 Jan 30.


Lactate transporters in the context of prostate cancer metabolism: what do we know?

Pértega-Gomes N, Baltazar F.

Int J Mol Sci. 2014 Oct 13;15(10):18333-48. doi: 10.3390/ijms151018333. Review.


T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness.

Pinto F, Pértega-Gomes N, Pereira MS, Vizcaíno JR, Monteiro P, Henrique RM, Baltazar F, Andrade RP, Reis RM.

Clin Cancer Res. 2014 Sep 15;20(18):4949-61. doi: 10.1158/1078-0432.CCR-14-0421. Epub 2014 Jul 9.


A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer.

Pértega-Gomes N, Vizcaíno JR, Attig J, Jurmeister S, Lopes C, Baltazar F.

BMC Cancer. 2014 May 21;14:352. doi: 10.1186/1471-2407-14-352.


Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer.

Zecchini V, Madhu B, Russell R, Pértega-Gomes N, Warren A, Gaude E, Borlido J, Stark R, Ireland-Zecchini H, Rao R, Scott H, Boren J, Massie C, Asim M, Brindle K, Griffiths J, Frezza C, Neal DE, Mills IG.

EMBO J. 2014 Jun 17;33(12):1365-82. doi: 10.15252/embj.201386874. Epub 2014 May 16.


Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer.

Pértega-Gomes N, Vizcaíno JR, Gouveia C, Jerónimo C, Henrique RM, Lopes C, Baltazar F.

Prostate. 2013 May;73(7):763-9. doi: 10.1002/pros.22620. Epub 2012 Nov 28.


Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer.

Pértega-Gomes N, Vizcaíno JR, Miranda-Gonçalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, Baltazar F.

BMC Cancer. 2011 Jul 25;11:312. doi: 10.1186/1471-2407-11-312.

Supplemental Content

Loading ...
Support Center